Develop and scale your process

The current targeting agent of choice for Antibody-Drug Conjugates (ADCs) is an intact antibody. Our experts in mammalian manufacturing begin the process by using our proprietary expression systems to produce and purify the antibody of choice which is designed for stochastic (random), or site-specific conjugation.

If an antibody fragment (Fab), single-chain variable fragment (scFv), or peptide aptamer is required for your targeting agent or carrier protein, our mammalian or microbial manufacturing team is ready to develop and scale your process.

microbial large-scale facility BPMP1/P2

Access state-of-the-art antibody or recombinant protein capabilities

Our capabilities include:

  • Protein engineering, humanization, immunogenicity and manufacturing assessment. LightPath™ discovery (non-GMP protein expression using GS System® vectors)
  • Cell line or bank engineering (incl. expression vectors for site-selective conjugation) cell line development, banking and stability LightPath™ development
  • Analytical method development/optimization and qualification/validation to support commercial filings including ELISA and bioassay
  • Process transfer, optimization, characterization/qualification/validation and viral clearance, pilot-scale manufacturing
  • cGMP clinical and commercial manufacturing release testing and regulatory writing services
  • Reference standard characterization and product stability studies
visp tech walking to computer
Our locations
Locations where this service is provided
Regulatory expertise
Pathway to success in Regulatory filings
Related Insights